Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ulcerative colitis
Biotech
Prometheus team returns with brand-new biotech and $400M
A brand-new biotech called Mirador has emerged from the team behind Prometheus Biosciences with a massive $400 million series A funding round.
Annalee Armstrong
Mar 21, 2024 7:00am
Aclaris lays off 46%, resurrects zunsemetinib for cancer
Dec 20, 2023 6:09am
InDex's ulcerative colitis drug fails interim phase 3 review
Nov 22, 2023 6:37am
Roche pays $7B to challenge Merck for bowel disease market
Oct 23, 2023 6:00am
Ventyx misses with investors amid comparisons to BMS, Pfizer
Oct 10, 2023 6:30am
Sanofi pays Teva $500M to join red-hot bowel disease race
Oct 4, 2023 6:00am